On this video, Jeff Yu, MD, MS, highlighted analysis on OX40 inhibitors and the way they inhibit T cells and from the Revolutionizing Atopic Dermatitis assembly.
The presentation, given by Christopher Bunick, MD, PhD, highlighted the promising knowledge proven from rocatinlumab in addition to knowledge which can be to come back from amlitelimab.
“I like to listen to about how doubtlessly we’re not simply speaking about treating atopic dermatitis in the interim, however we’re actually speaking about possibly modifying the illness going into the long run. So, I believe for me, that was a very eye-opening session,” stated
